Enhancement by hydrazine sulfate of antitumor effectiveness of cytoxan, mitomycin C, methotrexate and bleomycin, in walker 256 carcinosarcoma in rats.
Use of hydrazine sulfate potentiates the antitumor action of Cytoxan (cyclophosphamide), Mitomycin C, methotrexate and bleomycin against Walker 256 intramuscular carcinosarcoma in in vivo short-term studies in rats.  Experimental data suggest this potentiation by hydrazine sulfate to result from a mechanism of action other than direct cytotoxicity, and further, that combination chemotherapy with hydrazine sulfate and a cytotoxic agent may be useful in the treatment of human cancer.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001761:Bleomycin / Q000627:therapeutic use; D002279:Carcinoma 256, Walker / Q000188:drug therapy*; D002455:Cell Division / Q000187:drug effects; D003520:Cyclophosphamide / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006834:Hydrazines / Q000494:pharmacology*; D008937:Mitomycins / Q000627:therapeutic use; D051381:Rats
D000970:Antineoplastic Agents; D006834:Hydrazines; D008937:Mitomycins; D001761:Bleomycin; D003520:Cyclophosphamide